ASCO 2024 | Tuvusertib and niraparib in advanced unresectable solid tumors

Timothy Yap • 31 May 2024

ASCO 2024

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, explores findings from a Phase I trial (NCT04170153) of tuvusertib, an oral ATR inhibitor, with niraparib in patients with metastatic or locally advanced unresectable solid tumors. Tuvusertib and niraparib, administered in a one week on and one week off schedule, showed a manageable safety profile and promising efficacy in various cancer types, including PARP inhibitor-resistant tumors. This combination will be further explored in cases resistant to PARP inhibitors in the advanced ovarian cancer setting during the D-DRAIVER Ovarian 302 trial (NCT05216250). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Stock and Other Ownership Interests – Seagen
Consulting or Advisory Role – 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding – Acrivon Therapeutics; Artios; AstraZeneca; Bayer; BeiGene; BioNTech; Blueprint Medicines; BMS; Boundless Bio; Clovis Oncology; Constellation Pharmaceuticals; Cyteir; EMD Serono; F-Star; Forbius; Genentech; GlaxoSmithKline; Haihe Biopharma; IDEAYA Biosciences; ImmuneSensor Therapeutics; InSilico Medicine; Ionis Pharmaceuticals; Ipsen; Jounce Therapeutics; Karyopharm Therapeutics; KSQ Therapeutics; Kyowa Hakko Kirin; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Repare Therapeutics; Ribon Therapeutics; Rubius Therapeutics; Sanofi; Scholar Rock; Seagen; Tango Therapeutics; Tesaro; Vivace Therapeutics; Zenith Epigenetics